These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 660443)

  • 81. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
    Fahmy RH; Kassem MA
    Eur J Pharm Biopharm; 2008 Aug; 69(3):993-1003. PubMed ID: 18396390
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Influence of deposition and spray pattern of nasal powders on insulin bioavailability.
    Pringels E; Callens C; Vervaet C; Dumont F; Slegers G; Foreman P; Remon JP
    Int J Pharm; 2006 Mar; 310(1-2):1-7. PubMed ID: 16427222
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Effect of dissolving pH of enteric coating agent on bioavailability of enteric coated tablets of erythromycin in man (author's transl)].
    Watanabe Y; Sano M; Motohashi K; Yoneda R
    Yakugaku Zasshi; 1978 Aug; 98(8):1092-100. PubMed ID: 30834
    [No Abstract]   [Full Text] [Related]  

  • 84. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
    Moutasim MY; ElMeshad AN; El-Nabarawi MA
    Drug Deliv Transl Res; 2017 Jun; 7(3):450-459. PubMed ID: 28283842
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components.
    Weyenberg W; Bozdag S; Foreman P; Remon JP; Ludwig A
    Eur J Pharm Biopharm; 2006 Feb; 62(2):202-9. PubMed ID: 16209917
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Interactions between macromolecular adjuvants and drugs. Part 18: The binding behaviour of sodium carboxymethylcellulose and other macromolecules towards streptomycin sulphate (author's transl)].
    Keipert S; Voigt R
    Pharmazie; 1979; 34(9):548-51. PubMed ID: 542488
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Enhanced bioavailability of digoxin from silica matrix formulations (author's transl)].
    Flasch H; Asmussen B; Heinz N
    Arzneimittelforschung; 1978; 28(2):326-30. PubMed ID: 205226
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [The influence of temperature on disintegration and dissolution time of tablets with a cellulose component as a binder (author's transl)].
    Delonca H; Joachim J; Mattha A
    J Pharm Belg; 1978; 33(3):171-8. PubMed ID: 682103
    [No Abstract]   [Full Text] [Related]  

  • 89. [Bioavailability study of a preparation of enteric-coated tablets of sodium fluoride (author's transl)].
    Lorent M; Gervois JP; Sondagh J; Dodion L
    J Pharm Belg; 1979; 34(5):272-8. PubMed ID: 512829
    [No Abstract]   [Full Text] [Related]  

  • 90. Effects of drying methods on the physicochemical and compressional characteristics of Okra powder and the release properties of its metronidazole tablet formulation.
    Bakre LG; Jaiyeoba KT
    Arch Pharm Res; 2009 Feb; 32(2):259-67. PubMed ID: 19280157
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Ordered mixing (author's transl)].
    Verraes J; Kinget R
    J Pharm Belg; 1979; 34(5):297-307. PubMed ID: 512832
    [No Abstract]   [Full Text] [Related]  

  • 92. Observations on the electrolyte sensitivity of CMC as tablet disintegrant.
    Ujfalussy G; Erdös S
    Pharmazie; 1982 Sep; 37(9):673-4. PubMed ID: 7146078
    [No Abstract]   [Full Text] [Related]  

  • 93. [Radical formation in the mixed powders of starch and silicates (author's transl)].
    Yokoi H; Kashiwagi H; Enomoto S; Takahashi H
    Yakugaku Zasshi; 1979 Sep; 99(9):914-8. PubMed ID: 232716
    [No Abstract]   [Full Text] [Related]  

  • 94. [Pharmaceutical applications of cyclodextrin complexations (author's transl)].
    Uekama K
    Yakugaku Zasshi; 1981 Oct; 101(10):857-73. PubMed ID: 7040632
    [No Abstract]   [Full Text] [Related]  

  • 95. EFFECT OF CERTAIN TABLET FORMULATION FACTORS ON DISSOLUTION RATE OF THE ACTIVE INGREDIENT. II. GRANULE SIZE, STARCH CONCENTRATION, AND COMPRESSION PRESSURE.
    LEVY G; ANTKOWIAK JM; PROCKNAL JA; WHITE DC
    J Pharm Sci; 1963 Nov; 52():1047-51. PubMed ID: 14079629
    [No Abstract]   [Full Text] [Related]  

  • 96. [Production of perhepar powder by means of spray drying].
    Wayer M; Kata M; Kedvessy G
    Acta Pharm Hung; 1984 Mar; 54(2):64-8. PubMed ID: 6730976
    [No Abstract]   [Full Text] [Related]  

  • 97. [Visco-plastic behavior of powder in the process of dynamic compression (author's transl)].
    Horikoshi I; Morii M; Nakabayashi S; Takeguchi N; Kimura M
    Yakugaku Zasshi; 1979 Apr; 99(4):325-8. PubMed ID: 480130
    [No Abstract]   [Full Text] [Related]  

  • 98. [Packing-property of pharmaceutical powders. VI. Relationship between compacting progress and measurements variation of apparent density in course of packing of pharmaceutical powders (author's transl)].
    Miyake Y; Toyoshima S; Takenaka H
    Yakugaku Zasshi; 1976 Jan; 96(1):116-21. PubMed ID: 943501
    [No Abstract]   [Full Text] [Related]  

  • 99. [On the volatility of ethylenediamine from aminophylline (author's transl)].
    Ishiguro Y; Sawada M; Ohmayu K; Kawabe K
    Yakugaku Zasshi; 1982 Jan; 102(2):211-4. PubMed ID: 7108752
    [No Abstract]   [Full Text] [Related]  

  • 100. [Bioavailability of nitrofurantoin; II: Quantitative determination nitrofurantoin in blood serum (author's transl)].
    Ebel S; Liedtke R; Missler B; Richter M; Surmann P
    Arch Pharm (Weinheim); 1979 Aug; 312(8):697-703. PubMed ID: 496585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.